Does a targeting ligand influence nanoparticle tumor localization or uptake?
Authors:
- 1 October 2008
- journal article
- Published by Elsevier in Trends in Biotechnology
- Vol. 26 (10) , 552-558
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Hydrophobization and bioconjugation for enhanced siRNA delivery and targetingRNA, 2007
- Exploiting EPR in Polymer Drug Conjugate Delivery for Tumor TargetingCurrent Pharmaceutical Design, 2006
- Recent Developments in the Application of Plasmid DNA-Based Vectors and Small Interfering RNA Therapeutics for CancerHuman Gene Therapy, 2006
- Pharmacokinetics and Pharmacodynamics of Lipidic Nano-Particles in CancerAnti-Cancer Agents in Medicinal Chemistry, 2006
- Exploiting the enhanced permeability and retention effect for tumor targetingDrug Discovery Today, 2006
- Gene therapy progress and prospects: non-viral gene therapy by systemic deliveryGene Therapy, 2006
- Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticlesInternational Journal of Pharmaceutics, 2006
- Pharmacokinetic Consequences of PegylationDrug Delivery, 2006
- PEGylation, successful approach to drug deliveryDrug Discovery Today, 2005
- The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targetingAdvances in Enzyme Regulation, 2001